L3VLUP
ProSign in

ILMN · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ILMNJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ILMN
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterILMNJNJ
Q3 202019 holders, $9.2bn30 holders, $26.2bn
Q4 202022 holders, $11.9bn32 holders, $26.6bn
Q1 202127 holders, $13.7bn31 holders, $25.3bn
Q2 202123 holders, $16.3bn37 holders, $25.6bn
Q3 202131 holders, $14.7bn40 holders, $24.1bn
Q4 202122 holders, $13.3bn33 holders, $25.2bn
Q1 202220 holders, $12.1bn35 holders, $28.2bn
Q2 202221 holders, $6.3bn33 holders, $26.9bn
Q3 202218 holders, $7.3bn36 holders, $25.4bn
Q4 202213 holders, $7.7bn35 holders, $27.6bn
Q1 202322 holders, $8.9bn42 holders, $24.5bn
Q2 202315 holders, $6.8bn38 holders, $25.0bn
Q3 202314 holders, $4.6bn37 holders, $18.9bn
Q4 202321 holders, $3.6bn31 holders, $19.0bn
Q1 202416 holders, $3.4bn32 holders, $19.7bn
Q2 202422 holders, $2.3bn35 holders, $20.4bn
Q3 202422 holders, $2.9bn28 holders, $22.3bn
Q4 202416 holders, $4.1bn37 holders, $20.4bn
Q1 202511 holders, $2.3bn32 holders, $20.5bn
Q2 20258 holders, $2.5bn31 holders, $18.4bn
Q3 20259 holders, $2.9bn32 holders, $23.7bn
Q4 202510 holders, $4.6bn29 holders, $27.8bn
Q1 202613 holders, $3.9bn34 holders, $35.6bn
Q2 202613 holders, $5.9bn33 holders, $39.1bn
ILMN

Illumina Inc

Holders
10
Reported value
$4.6bn
Buyers
21
Sellers
14

Breadth +7 among 92 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ILMN (3)

ARK Investment Management LLC, Baillie Gifford & Co, Renaissance Technologies LLC

Only JNJ (22)

AllianceBernstein LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Man Group PLC, Markel Group Inc, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →